We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Electronic Capsule Technology the Basis for Innovations in Personalized Medicine for Women

By LabMedica International staff writers
Posted on 30 Jan 2013
Two European biomedical companies have agreed to collaborate on the development of personalized diagnostic and therapeutic products in the area of women’s health.

Medimetrics BV (Heilbronn, Germany) and the newly formed LiGalli (The Hague, the Netherlands) will be pooling their expertise to develop and produce medical drug delivery and monitoring devices based on Medimetrics' IntelliCap electronic capsule. More...


The IntelliCap electronic capsule is a unique ingestible device that combines five technologies: electronically controlled drug release, laboratory measurement capability, GI tract navigation in the body, two-way real time communication, and the novel operating system. The capsule contains a fluid reservoir and a micro-fluidic pump capable of pumping fluids, pastes, or suspensions. Operation of the pump is controlled by an integrated microprocessor. The IntelliCap also contains sensors that measure the pH and temperature of the pill’s local environment and an ultralow power radio transceiver that allows two-way communication to a data-monitoring/control unit. It is powered by an on-board battery and its electronics are fully sealed to ensure biocompatibility.

LiGalli will contribute its in-depth experience in pharmaceutical and gynecological products to the partnership.

Dr.Willem de Laat, founder of LiGalli said, “This is a significant, but also a logical, step forward in the move towards personalized medicine, improving the diagnostic and therapeutic tools available to patients. Having access to this groundbreaking technology opens the door to developing individualized therapies, which for the first time could meet a woman’s specific needs. It then becomes possible to perform continuous diagnosis monitoring or time exactly when a therapy was delivered, adapt the quantity, and even interrupt the schedule, if necessary.”

Dr. Olaf Weiner, CEO of Medimetrics, said, “The new collaboration adds an exciting dimension within the area of women’s health, creating new and improved therapeutic opportunities for patients. More and more companies are recognizing the potential of our IntelliCap technology, seeking to capitalize on its diagnostic and drug delivery functionalities. It is already widely used by the pharmaceutical industry to rationalize and speed up the development of modified release formulations and dosage forms. By tailoring drug delivery in this way, it is also possible for patients to take their medication less frequently without compromising on efficacy.”

Related Links:
Medimetrics B.V.



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.